Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IC 100 - InflamaCORE/ZyVersa Therapeutics

Next Previous
Drug Profile

IC 100 - InflamaCORE/ZyVersa Therapeutics

Alternative Names: IC 100-01; IC 100-02; IC 100-03; IC 100-04; IC 100-05; IC 100-06; IC 100-07; IC 100-08; IC100 - ZyVersa Therapeutics/InflamaCORE; ICCN-100; Inflammasome ASC Inhibitor IC-100

Latest Information Update: 14 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator InflamaCORE; University of Miami
  • Developer InflamaCORE; ZyVersa Therapeutics
  • Class Anti-inflammatories; Antidementias; Eye disorder therapies; Hepatoprotectants; Monoclonal antibodies; Urologics; Vascular disorder therapies
  • Mechanism of Action AIM2 protein modulators; Cytokine inhibitors; Inflammasome inhibitors; NLRP3 protein modulators; PYCARD protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Alzheimer's disease; Atherosclerosis; Metabolic disorders; Multiple sclerosis; Parkinson's disease; Retinal disorders
  • Research Autoimmune disorders
  • Discontinued Adult respiratory distress syndrome

Most Recent Events

  • 01 Apr 2026 ZyVersa Therapeutics announces intention to submit IND to initiate phase I trial in Obesity in fourth quarter of 2026
  • 10 Sep 2025 Pharmacodynamics data from a preclinical studies in Metabolic disorders released by ZyVersa Therapeutics
  • 10 Sep 2025 ZyVersa Therapeutics plans to initiate an IND-enabling IC 100 preclinical study in a diet induced obesity (DIO) model in the fourth quarter of 2025

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top